Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan

被引：0
|
作者：
Suzuki, Sho [1 ,2 ]
Ishibashi, Fumiaki [1 ,2 ]
Gotoda, Takuji [3 ]
机构：
[1] Int Univ Hlth, Dept Gastroenterol, Ichikawa, Japan
[2] Welf Ichikawa Hosp, Ichikawa, Japan
[3] Nihon Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Tokyo, Japan
来源：
INTERNAL MEDICINE | 2023年 / 62卷 / 16期
关键词：
Helicobacter pylori; clarithromycin resistance; penicillin allergy; vonoprazan; THERAPY;
D O I：
10.2169/internalmedicine.1282-22
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2299 / 2300
页数：2
相关论文
共 50 条
  • [31] Vonoprazan on the Eradication of Helicobacter pylori Infection
    Huang, Jiaming
    Lin, Ye
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (03) : 221 - 226
  • [32] Efficacy of Vonoprazan for Helicobacter pylori Eradication
    Kiyotoki, Shu
    Nishikawa, Jun
    Sakaida, Isao
    INTERNAL MEDICINE, 2020, 59 (02) : 153 - 161
  • [33] Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study
    Han, Ying-Ying
    Zhou, Lin
    Hu, Yun-Lian
    Ding, Xiang-Wu
    Long, Hui
    Liu, Fei
    Xu, Ming
    Zhang, Zhen-Yu
    Li, Shuang-Ling
    Wang, Qiu-Yan
    Su, Cheng-Xia
    Chen, Yan
    Chen, Jie
    Lin, Ya
    Li, Pei-Yuan
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1167 - 1177
  • [34] Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori
    Bunchorntavakul, Chalermrat
    Buranathawornsom, Arunluk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (12) : 3308 - 3313
  • [35] The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
    Sue, Soichiro
    Kuwashima, Hirofumi
    Iwata, Yuri
    Oka, Hiroyuki
    Arima, Isao
    Fukuchi, Takehide
    Sanga, Katsuyuki
    Inokuchi, Yasuhiro
    Ishii, Yuniba
    Kanno, Masatomo
    Terada, Masahiro
    Amano, Hitoshi
    Naito, Makoto
    Iwase, Shigeru
    Okazaki, Hiroshi
    Komatsu, Kazuto
    Kokawa, Atsushi
    Kawana, Ichiro
    Morimoto, Manabu
    Saito, Toshifumi
    Kunishi, Yosuke
    Ikeda, Akihiko
    Takahashi, Daisuke
    Miwa, Haruo
    Sasaki, Tomohiko
    Tamura, Toshihide
    Kondo, Masaaki
    Shibata, Wataru
    Maeda, Shin
    INTERNAL MEDICINE, 2017, 56 (11) : 1277 - 1285
  • [36] Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
    Sue, Soichiro
    Shibata, Wataru
    Sasaki, Tomohiko
    Kaneko, Hiroaki
    Irie, Kuniyasu
    Kondo, Masaaki
    Maeda, Shin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) : 686 - 692
  • [37] Metronidazole sensitivity testing of Helicobacter pylori: the importance of media
    Taylor, KJ
    Edwards-Jones, V
    Armitage, M
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 1998, 55 (02) : 118 - 122
  • [38] Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis
    Su, Na-Yun
    Shi, Qing
    Mei, Hao
    Hu, Jie
    Liu, Yu-Xiang
    Liu, Han-Ning
    Liu, Heng-Qi
    Guo, Yan
    Wang, Xing-wei
    Lan, Chun-Hui
    HELICOBACTER, 2023, 28 (05)
  • [39] Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States
    Yunusa, Ismaeel
    Love, Bryan L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (04) : 635 - 644
  • [40] Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
    Hiroki Tanabe
    Keiichi Yoshino
    Katsuyoshi Ando
    Yoshiki Nomura
    Katsuhisa Ohta
    Kiichi Satoh
    Eiichiro Ichiishi
    Akiei Ishizuka
    Takaaki Otake
    Yutaka Kohgo
    Mikihiro Fujiya
    Toshikatsu Okumura
    Annals of Clinical Microbiology and Antimicrobials, 17
12345